All studies
Not yet recruitingPhase I/IIInterventional

An early-stage clinical trial to establish whether a new type of antibacterial (known as SASPject PT3.9) is a safe and effective way of treating people living with cystic fibrosis who have lung infections caused by the bacterium, Pseudomonas aeruginosa

People living with cystic fibrosis often develop long-lasting chest infections caused by a bacterium called Pseudomonas aeruginosa. Over time, these bacteria can become very difficult to treat with standard antibiotics. This clinical trial, named STEPS-CF, tests an innovative medicine called SASPject PT3.9. SASPject PT3.9 is a type of 'phage therapy'. It uses modified, natural viruses that specifically target and destroy bacteria without harming human cells. The study aims to check how safe this new medicine is, how well the body copes with it, and how effectively it reduces bacteria in the lungs. The trial is taking place in England for adults aged 18 to 60. Treatment is given as a drip into a vein. Participants will have regular health checks, lung tests, and sputum samples taken over about nine weeks to monitor their safety and wellbeing throughout.

At a glance

Status
Not yet recruiting
Phase
Phase I/II
Sponsor
SASPiPhi Limited
Enrolment target
64
Start
01 Jan 2027
Estimated completion
31 Dec 2028

What is this study about?

Cystic fibrosis is an inherited condition that causes thick, sticky mucus to build up inside the lungs. This environment makes it easy for bacteria, particularly a germ called Pseudomonas aeruginosa, to settle and cause repeated chest infections. Over years of treatment, these bugs can become resistant to common antibiotics, making new and different ways of fighting infections urgently needed.

This trial investigates a treatment called SASPject PT3.9. It works through phage therapy, which uses specially adapted viruses that naturally hunt down and destroy specific bacteria. Because these viruses only attack bacteria, they leave healthy human cells alone. The goal is to provide a powerful new weapon against Pseudomonas infections when standard antibiotics are no longer working well.

The STEPS-CF study is an early-stage clinical trial, meaning it is one of the first times this medicine is being given to people. Researchers want to make sure it is safe, find the right dose, and see how well it works. The trial is run in careful, small steps, starting with low doses and closely watching each person before moving on to higher amounts.

By taking part, participants help doctors learn whether phage therapy could become a reliable new treatment option for people with cystic fibrosis, potentially offering better lung health and fewer severe chest flare-ups in the future.

Key takeaways

  • Tests an innovative phage-based treatment designed to kill Pseudomonas lung bacteria.
  • Open to adults aged 18 to 60 with cystic fibrosis who can produce sputum samples.
  • Medicine is given through an intravenous drip in a hospital research clinic.
  • Involves close health monitoring, breathing checks, and follow-up for up to 63 days.
  • Participation is entirely voluntary and runs alongside standard cystic fibrosis care.

Who may be eligible?

This trial is open to adults aged 18 to 60 who have a confirmed diagnosis of cystic fibrosis. Participants must currently have a Pseudomonas aeruginosa lung infection that tests show can be treated by SASPject PT3.9, and they must be able to cough up sputum samples for lab testing.

To ensure it is safe to take part, your lung function (measured by a breathing test called FEV1) needs to be at least 40% of what is expected for your age and height. Your regular cystic fibrosis treatments, including any CFTR modulator drugs, must have stayed the same for at least three months before joining.

You cannot join the trial if you weigh under 30 kg, are currently pregnant or breastfeeding, or have recently taken medication for fungal or mycobacterial infections. Because the medicine is new, both men and women must agree to use reliable contraception during the study and for four months afterwards.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. You are an adult aged between 18 and 60.
  2. You have a confirmed medical diagnosis of cystic fibrosis.
  3. You have had a Pseudomonas lung infection in the past 12 months.
  4. You are able to cough up sputum for testing at clinic visits.
  5. Your lung function (FEV1) is at or above 40%.
  6. Your cystic fibrosis medications have been stable for at least 3 months.
Answer every question to see your result.

What does participation involve?

Taking part lasts for up to 63 days (around nine weeks). You will visit a specialist clinical research unit in England, where you may need to stay for short periods or attend day visits. The trial medicine (or a dummy version called a placebo) is given through a slow drip directly into a vein. You will have regular health checks, including blood tests, breathing tests (spirometry), and sputum checks to see how many bacteria remain in your lungs. You will also be asked to complete simple questionnaires about your daily wellbeing. Qualified medical staff will watch over you closely during every treatment and visit, and travel expenses or compensation for your time are provided.

Potential risks and benefits

You may benefit from a reduction in your chest infection, although as this is an early-stage study, direct health benefits cannot be guaranteed. You will receive very thorough medical attention and regular check-ups from lung specialists. The main risks include mild pain, redness, or swelling where the drip enters your vein, temporary discomfort during blood tests, or unexpected reactions to a new medicine. Doctors monitor you for at least eight hours after every dose to treat any side effects quickly. Taking part is completely voluntary, and you are free to leave the trial at any point without it affecting your usual NHS cystic fibrosis care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • NIHR Liverpool Clinical Research Facility
    City only
    Liverpool, England

Common questions

What is phage therapy?

Phage therapy uses harmless, natural viruses that only target and kill specific bacteria. They cannot infect human cells, making them a focused tool against stubborn chest bugs.

Will I definitely receive the new medicine?

Not necessarily. In some parts of the trial, participants are randomly chosen to receive either the active medicine or an inactive dummy drip (placebo), so doctors can make a fair comparison.

Do I have to stop my regular cystic fibrosis treatments?

No, you can continue your usual stable cystic fibrosis medications, but your routine prescriptions must not have changed in the three months before joining.

Is the treatment painful?

The medicine is given via a small needle into a vein, which may cause a brief pinch or minor bruising, similar to having a routine blood test.

What happens if I change my mind?

You can leave the trial at any time, for any reason. Your normal hospital care and relationship with your doctors will not be affected in any way.

How to find out more

- SASPiPhi Limited

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "An early-stage clinical trial to establish whether a new typ…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.